Introduction
============

Bladder cancer (BCa) is currently one of the most common cancers [@B1], but the underlying mechanism of the muscle-invasive or metastatic BCa has not been clarified yet [@B2]. Our group has completed a transcriptome analysis using BCa tissues and normal bladder epithelium [@B3]-[@B5], revealing several significantly affected related pathways and hundreds of genes. One of the most significantly upregulated genes in BCa tissue is the Holliday Junction Recognition Protein (HJURP), a histone chaperone in nucleosome involved in *de novo* histone H3 variant CenH3 (CENP-A) [@B6] and CENP-C recruitment [@B7]. HJURP has been reported to be able to regulate expansion of centromeric chromatin [@B8] and chromosomal stability [@B9]. Recent studies suggested that HJURP participated in the regulation of cell immortality in lung cancer [@B10] and breast cancer [@B11], and could be a new independent prognostic marker for breast cancer [@B12]-[@B14], indicating an important role of HJURP in human diseases [@B15]. Though the correlation between HJURP and bladder cancer has not been investigated yet, our transcriptome data [@B3],[@B4],[@B16] suggested that HJURP was involved in nucleosome assembly and cell cycle regulation in BCa. Our recent works showed that induction of cell cycle arrest could inhibit proliferation of urological cancer cells [@B17]-[@B19]. Therefore, we hypothesized that the alteration of HJURP expression level might affect cell cycle regulation and viability and thus functions in BCa cells.

Our transcriptome data also indicated that Peroxisome Proliferator-Activated Receptors (PPARs) [@B16] and Sirtuins [@B5] were involved in BCa cells. PPARs have been reported to be essential for the regulation of cell differentiation, lipid metabolism and tumourigenesis [@B20],[@B21]. Activation/deactivation of PPARs could affect genes related to cellular metabolism, proliferation, lipid peroxidation and stress response including reactive oxygen species (ROS) [@B22]. In addition, manipulating of PPAR activity by either agonist or antagonist has been considered as a potential treatment for metabolic diseases and cancer including BCa [@B23]-[@B25]. The nuclear receptor PPARγ, a key member of the PPAR family and involving in cell cycle regulation [@B26],[@B27], could bind to the promoter region of *SIRT1* to inhibit the transcription [@B28]. The deacetylase SIRT1 is the most investigated member of the Sirtuin family [@B29], and its role includes regulating aging [@B30], apoptosis [@B31],[@B32], anti-oxidative response [@B33],[@B34], ROS metabolism [@B35],[@B36] and linking inflammation and metabolism together [@B37]. Importantly, SIRT1 could function as key regulator to activate those genes regulating apoptosis and cell survival, such as PPARγ [@B38], PGC-1α [@B39], p53 [@B40],[@B41] as well as FoxO [@B42]. A recent study suggested the link between PPARγ and SIRT1 and a negative feedback loop of PPARγ-SIRT1 was proposed [@B28].

Inhibition of SIRT1 was previously reported to reduce cell proliferation, attenuate cell migration and prolong cell cycle progression [@B43] in human BCa, but the underlying molecular mechanism is still not characterized. Similar to SIRT1, *PPARγ* was observed overexpressed in bladder cancer [@B23],[@B44], but the functional role remains unclear. In the present study, we started with identifying the alterations of *HJURP* and related genes in the BCa tissues and have characterized the effects of *HJURP* in bladder cancers using several BCa cell lines through the PPARγ-SIRT1 feedback loop.

Materials and Methods
=====================

Ethical statement for human bladder tissue samples
--------------------------------------------------

As described by Cao *et al*[@B3], Chen *et al*[@B4] and Qian *et al*[@B5] from our group, bladder cancer tissue samples (n = 3) and normal bladder tissue samples (n = 3) were collected from male patients after surgery by radical resection and male donors undergoing transplantation by accidental death at Zhongnan Hospital of Wuhan University, Wuhan, China, respectively. These samples were stored in liquid nitrogen for total RNA isolation and microarray analysis. Bladder cancer tissue samples and paracancerous tissues (n = 20) were obtained from patient suffering bladder cancer, and then either stored in liquid nitrogen for total RNA isolation or fixed in 4% paraformaldehyde (PFA) for immunofluorescence staining analysis. Informed consent was obtained from all subjects. The Ethics Committee at Zhongnan Hospital of Wuhan University approved the experiments using human bladder tissue samples for RNA isolation and immunofluorescence staining analysis (approval number: 2015029). All methods used for human bladder tissue samples were performed in accordance with the approved guidelines and regulations.

Human bladder cancer cell lines
-------------------------------

Human bladder cancer cell lines UM-UC-3 (transitional cell carcinoma, Cat. \#TCHu217) and T24 (transitional cell carcinoma, Cat. \#SCSP-536) were kindly provided by the Stem Cell Bank, Chinese Academy of Sciences in Shanghai, China. The bladder cancer cell line EJ was purchased from the Procell Co. Ltd. (carcinoma, Cat. \#CL-0274) in Wuhan, China. Identification of the BCa cell lines was conducted at the China Centre for Type Culture Collection in Wuhan, China. The UM-UC-3 cell was cultured in DMEM (Gibco, China) and T24, EJ cells were cultured in RPMI-1640 medium (Gibco, China) containing 10% fetal bovine serum (FBS) (Gibco, Australia) and 1% penicillin G sodium/streptomycin sulphate in a humidified atmosphere consisting of 95% air and 5% CO~2~ at 37 ºC.

RNA expression analyses
-----------------------

### Total RNA isolation from bladder tissues and BCa cells

Total RNA from bladder cancer cells as well as bladder tissues were isolated with the Qiagen RNeasy Mini Kit (Cat. \#74101, Qiagen, Germany), and QIAshredder from Qiagen (Cat. \#79654, Qiagen, Germany) using a centrifuge (Cat. \#5424, Eppendorf, Germany) according to the manufacturer\'s protocol. DNase I (RNase-Free DNase Set, Cat. \#79254, Qiagen, Germany) was used digest each RNA sample to remove contamination of gDNA. The quantity of isolated RNA was measured by NanoPhotometer (Cat. \#N60, Implen, Germany).

### Microarray analysis of mRNA isolated from human bladder tissues

A microarray analysis was established using mRNA isolated from the three bladder cancer tissues and the three normal bladder tissues. Briefly, according to the standard Affymetrix protocol, 250 ng total RNA of each sample was prepared to biotinylated cDNA by Ambion^®^ WT Expression Kit. On GeneChip Human Transcriptome Array 2.0, 5.5 µg of cDNA were hybridized for 16 h at 45 ºC, continuously washed and stained in the Affymetrix Fluidics Station 450, scanned by Affymetrix^®^ GeneChip Command Console (AGCC) installed in GeneChip^®^ Scanner 3000 (7G). Data analysis was with a Robust Multichip Analysis (RMA) algorithm using Affymetrix default analysis settings and global scaling as normalization method. Bladder cancer related genes, pathways and functions were analyzed by Gene ontology (GO) and Pathway-Relation-Network (Path-net) analysis tools based on Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Database [@B45],[@B46] (<http://www.kegg.jp/kegg/kegg1.html>) using the Gene Cloud of Biotechnology Information (GCBI Platform, Shanghai, China). The resulting gene list was subjected to the Database for Annotation, Visualization and Integrated Discovery (DAVID) [@B47] as well for annotation and overrepresentation analysis of the genes involved in cell cycle pathway ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S1) and p53 signaling pathway ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S2). The microarray raw data was submitted to the Gene Expression Omnibus (GEO) database with accession number GSE76211. All data are MIAME compliant.

### Reverse transcription and quantitative real time PCR (qRT-PCR)

First-strand cDNA was synthesized by ReverTra Ace qPCR RT Kit (Toyobo, China) using 1 µg of total RNA isolated from bladder tissues or BCa cells. Each reaction of real-time polymerase chain reactions (PCR) was conducted with iQ^TM^ SYBR^®^ Green Supermix (Bio-Rad, China) in a final volume of 20 µl using 1 µg of cDNA. All primers were tested for optimal annealing temperatures and PCR conditions were optimized with gradient PCRs on an iCycler (Cat. \#CFX Connect, Bio-Rad, USA). Primer sequences and annealing temperatures are summarized in [Supplementary Table](#SM1){ref-type="supplementary-material"} S1. Values were normalized for amplified *GAPDH* alleles. Relative gene abundance = 2^-ΔΔct^, Δct = ct*~target\ gene~* - ct*~GAPDH~*, for BCa cells ΔΔct = Δct*~siRNA-treated~* - Δct*~siRNA-untreated~*, for bladder tissues ΔΔct = Δct*~BCa\ patients~* - Δct*~paracancerous\ tissues~* (ct = threshold cycle).

Cell culture experiments
------------------------

### Knockdown of *HJURP* and *CENP-A* in the BCa cells

Three*HJURP-target specific small interfering RNA* (*HJURP-siRNA*), three *CENP-A-target specific small interfering RNA* (*CENP-A-siRNA*) and one *control-siRNA* (NC) were synthesized by ViewSolid Ltd. in Beijing, China (sequences listed in [Supplementary Table](#SM1){ref-type="supplementary-material"} S2 and S3). Distinct BCa cells (T24, EJ and UM-UC-3) were transfected with *HJURP-target-specific-siRNA*, *CENP-A-target-specific- siRNA* and *control-siRNA* using lipoJet^TM^ (SignaGen, China), according to the manufacturer\'s protocol. After transfection by the three *HJURP-target-specific-siRNA* (*HJURP si-1*, *si-2* and *si-3*), the three *CEPN-A-target-specific-siRNA* (*CENP-A si-1*, *si-2* and *si-3*) and *control-siRNA* for 72 h, alterations of HJURP and CENP-A at transcriptional and protein levels were evaluated by qRT-PCR and immunofluorescence staining or Western blot analysis. The *HJURP si-2* and *CENP-A si-3* were used for the following experiments.

### Overexpression of *HJURP* in the BCa cells

The plasmid of *HJURP*-overexpression (*pWSLV-11-HJURP* vector) were synthesized by ViewSolid Ltd. in Beijing, China (sequences listed in Supplementary Sequences S1). The BCa cells (UM-UC-3, EJ and T24) were transfected by the *pWSLV-11-HJURP* vector to upregulate the expression of *HJURP* at the transcription level.

### Pre-treatment using PPARγ-antagonist and SIRT1-agonist for rescue experiments

Before *HJURP-siRNA* transfection, BCa cells were pre-treated by PPARγ-antagonist, GW9662 (Cat. \#M6191, Sigma-Aldrich, USA) at a final concentration 0, 20 and 40 µM or SIRT1-agonist resveratrol (RSV) (Cat. \#R5010, Sigma-Aldrich, USA) at a final concentration 0, 50 and 100 µM, for 12 h. Meanwhile, untreated BCa cells were also pre-incubated with appropriate amount of vehicle (0.1% DMSO). Then BCa cells were transfected by *siRNA* for another 72 h. Alterations of proliferation, ROS and cell cycle were measured by CCK-8 assay and flow cytometry analysis.

### Transwell migration assay

The transwell migration assay was conducted in 24-well plate transwell chamber system (Corning, USA) with 8.0 µm pore size. Distinct BCa cells were suspended in serum-free medium at a density of 40,000 - 60,000 cells per 100 µl and seeded in the upper chamber insert, while the lower chamber was filled with 10% FBS medium. After incubation for 24 h at 37 ºC, cotton swabs were used to remove the cells in the upper insert, and cells that migrated to the lower side were fixed with 4% PFA and stained with crystal violet. Then the chambers were placed under an inverted phase contrast microscope and to observe and count the migrated cells.

### CCK-8 assay

After transfection for 24 h, distinct BCa cells were seeded in 96-well plates (3,000-5,000 cells per 200 μl medium) to grow for another 5 days. After adding 20 μl CCK-8 (5 mg/ml) to each well and incubating for 1 h at 37 °C, absorbance at 450 nm was measured by a microplate reader (Cat. \#SpectraMax M2, Molecular Devices, USA).

### Clonogenic forming experiment

After transfection 24 h, distinct BCa cells were seeded in 6-well plates (1,000-1,500 cells per well) and grew into colonies for approximately 14 days. Then Colonies was fixed with 4% PFA for 30 min, staining with crystal violet, counted and photographed.

### Flow cytometry analysis for alterations of cell cycle and apoptosis

For cell cycle analysis, after indicated treatment, cells were harvested and centrifugated, then washed with PBS, pellets were resuspended with 1X DNA Staining Solution containing propidium iodide and permeabilization solution (Multi sciences, China) in the dark. BCa cells were cultured at 37 ºC for 30 min, cell cycle distribution was analyzed by flow cytometry analysis (Cat. \#FC500, Beckman, USA). Cell apoptosis analysis was assessed by FITC Annexin V Apoptosis Detection Kit I (BD biosciences, USA) according to the manufacturer\'s instructions and analyzed by the flow cytometry analysis.

### ROS detection by staining with DCFH-DA

Intracellular ROS level of the BCa cells was measured by the fluorescent probe 2\',7\'-Dichlorofluorescin diacetate (DCFH-DA, Sigma-Aldrich, USA). After indicated treatment, cells were trypsinized and centrifugated, then 10 µmol of DCFH-DA (Sigma, USA) was diluted into 1 ml serum-free medium and cultured at 37 °C for 30 min. Before submitted to flow cytometry analysis, cells were washed three times to remove the uncombined probe. For ROS staining, DCFH-DA and DAPI were added to the slides with the BCa cells and incubated 30 min at the room temperature (RT), then washed three times. Immunofluorescence staining was analyzed using a fluorescence microscope (Cat. \#IX73, Olympus, Japan).

### TUNEL assay

After 72 h transfection, coverslips with BCa cells were fixed by 4% PFA for 30 min at RT and washed three times by ice-cold PBS, continuously incubated with 0.1% Triton X-100 for 2 min and washed by PBS. Then the TdT-mediated dUTP-biotin nick end labeling test (TUNEL, Roche Applied Science, Germany) was used to detect apoptosis cells according to the manufacturer\'s instructions. Nuclei were counterstained with 1 µM DAPI for 20 min at RT. Images were taken with fluorescence microscope.

Protein Analyses
----------------

### Isolation of total protein from BCa cells and Western blot analysis

RIPA buffer containing protease inhibitor and phosphatase inhibitor (Sigma-Aldrich, USA) was used to lyse and sonicate cells on ice for 30 min, then centrifuged at 13,000 g for 15 min to collect supernatant. The concentrations of protein were determined by Bradford protein assay (Bio-Rad, Germany) using Bovine serum albumin (BSA) as standard. Briefly, total protein was separated using 10-12.5% SDS-PAGE and transferred to PVDF membrane (Millipore, USA). Membranes were then blocked in 5% fat-free milk and continuously incubated with primary ([Supplementary Table](#SM1){ref-type="supplementary-material"} S4) and secondary antibodies ([Supplementary Table](#SM1){ref-type="supplementary-material"} S5) overnight at 4 °C. Bands were visualized using an enhanced chemiluminescence (ECL) kit (Bio-Rad, USA) and photographed by ChemiDoc XRS^+^ system (Bio-Rad, USA).

### Immunofluorescence staining for human bladder tissue samples

All the bladder tissue samples were collected and histologically diagnosed by two experienced pathologists independently. The samples were fixed by 4% PFA containing 2% sucrose in PBS at 4 ºC overnight and embedded into paraffin (Paraplast, Sigma-Aldrich, USA) using a tissue processor (Cat. \#STP 120, Thermo Fisher Scientific, UK). Paraffin sections (4 µm) were cut with a rotation microtome (Cat. \#HM325, Thermo Fisher Scientific, Germany). The sections were serially incubated with indicated primary antibody and Cy3-labeled or FITC-labeled secondary antibody in humidified atmosphere (antibodies listed in [Supplementary Table](#SM1){ref-type="supplementary-material"} S4 and S5). Nuclei were labeled with DAPI (2 μg/ml). Paraffin sections were analyzed by fluorescence microscope.

### Immunofluorescence analysis for BCa cells

Coverslips with BCa cells were washed three times with ice cold PBS and fixed with 4% PFA for 30 min. Cells were then treated with 0.1% Triton X-100 solution and blocked in normal goat serum for 30 min at RT. Afterwards, cells were incubated with the indicated primary antibody ([Supplementary Table](#SM1){ref-type="supplementary-material"} S4) at the proper dilution for 2 h at RT, washed three times with PBS, and incubated with Cy3-labeled or FITC-labeled secondary antibody ([Supplementary Table](#SM1){ref-type="supplementary-material"} S5) for 1 h. Nuclei were visualized with DAPI (2 μg/ml) for 10 min at RT. Immunofluorescence staining was analyzed by fluorescence microscope.

Statistical analyses
--------------------

Data were expressed as mean ± SD from three independent experiments. All analyses were performed three times and represent data from three individual experiments. Two-tailed Student\'s t-tests were used to evaluate the statistical significance of differences of the data. All of the statistical analyses were performed with SPSS 16.0. The statistical significance was set at probability values of p\<0.05.

Results
=======

Bioinformatic analysis for BCa related pathways
-----------------------------------------------

Previously we performed a microarray analysis comparing BCa tissues with normal bladder tissues [@B3]-[@B5]. Gene ontology (GO) and Pathway-Relation-Network (Path-net) analysis revealed that cell cycle pathway as a key node, similar to Mitogen-Activated Protein Kinases (MAPK) signaling pathway, pathway in cancer and PPAR signaling pathway (Figure [1](#F1){ref-type="fig"}A). In addition, p53 signaling pathway was suggested as a link between bladder cancer and apoptosis (Figure [1](#F1){ref-type="fig"}A). The top thirty BCa related GO terms were listed in [Supplementary Table](#SM1){ref-type="supplementary-material"} S6 (ranked by p-value) and in [Supplementary Figure](#SM1){ref-type="supplementary-material"} S3 (ranked by enrichment score). These results suggested that GO terms associated with mitotic, nucleosome assembly, cell division and cell proliferation were enriched, suggesting dysregulated cell cycle regulation. Consistently, overrepresentation analysis based on DAVID database revealed that genes involved in cell cycle pathway were significantly affected in the BCa tissues ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S1).

Upregulation of HJURP in BCa samples compared with paracancerous tissues and normal bladder tissues
---------------------------------------------------------------------------------------------------

Since HJURP is ranked top in the affected genes involving the cell cycle, we further surveyed the Oncomine database ([www.oncomine.org](http://www.oncomine.org)). Compared with normal bladder tissues, the mRNA level of *HJURP* was strongly upregulated in BCa tissues ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S4), which is consistent with our microarray data ([Supplementary Table](#SM1){ref-type="supplementary-material"} S3). In order to confirm the results above, we performed qRT-PCR analysis to evaluate the expression of *HJURP*, indicating significant upregulation in the BCa tissues compared with the paired paracancerous tissues (n = 20, Figure [1](#F1){ref-type="fig"}B). Double immunofluorescence staining revealed strong signal of HJURP protein in OCT4-positive cells in the BCa tissues (Figure [1](#F1){ref-type="fig"}C), while the respective paracancerous bladder tissues and normal bladder tissues showed only weak staining of both OCT4 and HJURP protein (Figure [1](#F1){ref-type="fig"}C).

Inhibited proliferation and viability, rather than motility, in the BCa cells with reduced *HJURP*
--------------------------------------------------------------------------------------------------

To study the function of *HJURP* in bladder cancers, we constructed a cell model with reduced *HJURP* by *siRNA*-transfection in three BCa cell lines (UM-UC-3, EJ and T24). We transfected the BCa cells with three distinct *siRNA* specifically targeting *HJURP* and validated the efficient knockdown by qRT-PCR 72 h later (Figure [2](#F2){ref-type="fig"}A-C). Moreover, immunofluorescence staining also showed protein abundance of HJURP was strongly downregulated (Figure [2](#F2){ref-type="fig"}D), together indicating a successful BCa cell model with reduced *HJURP*. We further evaluated the cell growth ability and CCK-8 assay showed that *HJURP*-*siRNA*-treated BCa cells grew significantly slower than the control BCa cells (Figure [2](#F2){ref-type="fig"}E). Clonogenic survival assay revealed that the ability of colony formation was significantly decreased in the *HJURP*-*siRNA*-treated cells comparing with the control group (Figure [2](#F2){ref-type="fig"}F-G). Moreover, the *HJURP*-*siRNA*-treated group exhibited considerably less Ki-67 positive cells than the NC group (Figure [2](#F2){ref-type="fig"}H). No significant alteration of cell migration rate in the *HJURP*-*siRNA*-treated BCa cells was observed by transwell migration assay ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S5).

Increased cell apoptotic rate in the *HJURP-siRNA*-treated BCa cells
--------------------------------------------------------------------

Since we observed significantly impaired cell growth in *HJURP*-*siRNA*-treated BCa cells, we have investigated the apoptotic status of the BCa cells. Flow cytometry analysis revealed that the early apoptotic BCa cells were increased in the *HJURP*-*siRNA*-treated BCa cells, comparing with the control group in all three tested cell lines (Figure [3](#F3){ref-type="fig"}A-B). This result was further confirmed by TUNEL assay (Figure [3](#F3){ref-type="fig"}D-E). In addition, we observe the slightly alterations of cleaved Caspase 3, 7, 9 in the *HJURP*-*siRNA*-treated BCa cells (Figure [3](#F3){ref-type="fig"}C).

Downregulation of *HJURP*induced ROS generation in BCa cells, accompanied by interfering the PPARγ-SIRT1 feedback loop
----------------------------------------------------------------------------------------------------------------------

The cells transfected either *control-siRNA* (NC) or *HJURP-target-specific-siRNA*(*HJURP-siRNA*) for 72 h were stained with DCFH-DA and submitted to flow cytometry analysis. The results suggested that BCa cells lacking *HJURP* exhibited a higher ROS level than the NC group (Figure [4](#F4){ref-type="fig"}A-B). Consistently, alteration of ROS status was evaluated by ROS staining using fluorescence microscope as well, showing an increased ROS-positive cell rate in the *HJURP*-*siRNA*-treated group ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S6). Moreover, Western blot analysis revealed that proteins (Catalase, Hmox-1, SOD2) associated with ROS metabolism were all considerably upregulated in the *HJURP*-*siRNA*-treated group (Figure [4](#F4){ref-type="fig"}C), which was confirmed by the immunofluorescence analysis as well (Figure [4](#F4){ref-type="fig"}D). Furthermore, alterations of proteins involved in apoptosis were also evaluated by Western blot, suggesting an upregulation of the apoptosis inducer Bax [@B48] and downregulation of the pro-survival factor Bcl-xl [@B49] (Figure [4](#F4){ref-type="fig"}C). Importantly, both Western blot and immunofluorescence analysis could reveal that knockdown of *HJURP* could induce PPARγ and inhibit p-SIRT1/t-SIRT1 (Figure [4](#F4){ref-type="fig"}C-D), which could regulate ROS metabolism, apoptosis, cell cycle. In addition, we observed an increasing of acetylated p53 at protein level (Figure [4](#F4){ref-type="fig"}C) and especially in the nuclear region (Figure [4](#F4){ref-type="fig"}D) in the *HJURP*-*siRNA*-treated group, which is negatively controlled by SIRT1 deacetylase, linking metabolism and apoptosis together [@B41].

Downregulation of *HJURP*-triggered ROS induction and proliferation inhibition could be scavenged by pretreatment of PPARγ-antagonist and SIRT1-agonist
-------------------------------------------------------------------------------------------------------------------------------------------------------

The BCa cells (UM-UC-3 and EJ) were pretreated by GW9662 (PPARγ-antagonist), RSV (SIRT1-agonist) or DMSO (control), then transfected with indicated*siRNA.*The decrease viability of *HJURP KD* BCa cells\' proliferation could be rescued by GW9662 and RSV ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S7). Moreover, alteration of ROS level was measured by flow cytometry, showing the increasing of ROS due to reduction of *HJURP* could be significantly scavenged in the UM-UC-3 and EJ cells (Figure [4](#F4){ref-type="fig"}E-F). Furthermore, protein expression analysis suggested that Catalase protein was also decreased in the GW9662-pretreated *HJURP*-deficient BCa cells (Figure [4](#F4){ref-type="fig"}G).

Induction of cell cycle arrest at G0/G1 phase in the *HJURP-siRNA*-treated BCa cells
------------------------------------------------------------------------------------

Flow cytometry analysis was used to evaluate the alteration of cell cycle in *HJURP-siRNA*-treated BCa cells*,* compared with the NC group (Figure [5](#F5){ref-type="fig"}A). The results suggested a significant increase of cell population at G0/G1 phase and a significant reduction of cell population at S phase in the *HJURP*-*siRNA*-treated group (Figure [5](#F5){ref-type="fig"}B). In addition, we also analyzed the proteins involved in the G0/G1 phase regulation by Western blot, suggesting strong decrease of Cyclin A1/2 (CCNA1/2), Cyclin D1 (CCND1) and CDK2/4 in the *HJURP*-*siRNA*-treated group (Figure [5](#F5){ref-type="fig"}C). Furthermore, phosphorylated/total GSK-3β, an upstream indicator of cell cycle pathway [@B50], were considerably upregulated in the *HJURP*-*siRNA*-treated BCa cells. Moreover, ERK1/2, a key member in the MAPK family, was also affected in the *HJURP*-*siRNA*-treated BCa cells (Figure [5](#F5){ref-type="fig"}C), indicating ERK1/2 was strongly deactivated. In contrast, Western blot analysis showed that JNK/p38 pathway was not significantly activated ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S8).

Rescued cell cycle arrest due to reduced*HJURP* upon PPARγ antagonist treatment in BCa cells
--------------------------------------------------------------------------------------------

To investigate the role of PPARγ-SIRT1 feedback loop in the cell cycle arrest induced by *HJURP*-*siRNA* treatment, PPARγ-antagonist (GW9662) was used to deactivate function of PPARγ protein. After pretreatment with GW9662 at distinct concentration for 12 h, BCa cells (UM-UC-3 and EJ) were then transfected by *siRNA* for another 72 h. Flow cytometry analysis showed deactivation of PPARγ could recover the cell cycle arrest at G0/G1 phase triggered by *HJURP* deficiency (Figure [6](#F6){ref-type="fig"}A-B), as demonstrated by upregulation of CCNA1/2, CCND1 and CDK2/4 in *HJURP*-*siRNA*-treated group evaluated by Western blot (Figure [6](#F6){ref-type="fig"}C). We also observed that treatment of GW9662 could not suppress PPARγ at protein level, but indeed induce both p-SIRT1 and t-SIRT1 (Figure [6](#F6){ref-type="fig"}C).

Positive correlation between CENP-A and HJURP in the BCa cells
--------------------------------------------------------------

To investigate the correlation of CENP-A and HJURP in the BCa cells, we analyzed the alteration of CENP-A protein abundance in the *HJURP-siRNA*-treated and *HJURP*-overexpressed BCa cells (UM-UC-3, T24 and EJ). Western blot analysis revealed a strong decrease of CENP-A in the BCa cells with reduced *HJURP* (Figure [7](#F7){ref-type="fig"}A), whereas an increasing protein level of CENP-A in the *HJURP*-overexpressing cells (Figure [7](#F7){ref-type="fig"}B), suggesting a positive correlation between CENP-A and HJURP. Moreover, the BCa cells with reduced *CENP-A* showed a similar cell cycle arrest at G0/G1 phase (Figure [7](#F7){ref-type="fig"}D-E) as the *HJURP-siRNA*-treated cells (Figure [5](#F5){ref-type="fig"}A-B), as well as a similar reduction of the proteins (CCND1, CDK2) involved in cell cycle regulation (Figure [7](#F7){ref-type="fig"}C).

Discussion
==========

Our group has comprehensively analyzed the transcriptome data of bladder cancer tissues versus normal bladder tissues [@B3]-[@B5]. Among hundreds of strongly altered genes involving in development of human bladder cancer (BCa), we observed an interesting gene named *HJURP*. In consist with our results (Figure [1](#F1){ref-type="fig"}B), Oncomine database points out the transcription level of *HJURP* was significantly upregulated in the human bladder cancer tissues as well ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S4). HJURP has been reported to be involved in nucleosome assembly and a key chaperone of CENP-A, which is positively correlated with HJURP in human bladder cancer cells as well (Figure [7](#F7){ref-type="fig"}A-B), ensuring its safe delivery, incorporation, and maintenance at centromeres in a cell cycle dependent way [@B51]. Recent studies revealed that HJURP was correlated with lung cancer [@B10] and breast cancer [@B11]. Here we focused on the functional role of *HJURP* in BCa. First we confirmed the overexpression of HJURP in BCa tissues at both transcriptional and protein levels (Figure [1](#F1){ref-type="fig"}B-C). Immunofluorescence co-staining in BCa tissues indicated a co-localization of HJURP and a potential bladder cancer cell marker OCT4 [@B52]. Then using the *HJURP*-*siRNA*-treated cells, we observed that reduced *HJURP* resulted in an inhibitory effect on cell growth, colony formation ability and Ki-67 positive cells (Figure [2](#F2){ref-type="fig"}), whereas migration rate remained unaffected ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S5).

More interestingly, we observed that *HJURP*-*siRNA*-treated BCa cells exhibited a significantly higher apoptotic rate than the control group, with slightly upregulation of distinct cleaved Caspases (Figure [3](#F3){ref-type="fig"}), which plays normally a central role in the execution of apoptosis [@B53]. Interestingly, Western blot analysis revealed a remarkably increasing of Bax, an inducer of apoptosis [@B48], and strongly decreasing of Bcl-xl, an pro-survival factor [@B49] (Figure [4](#F4){ref-type="fig"}C).

In addition, inhibition of apoptosis by Bcl-2 and Bcl-xl has been reported to be associated with protection against ROS and/or a shift of the cellular redox potential to a more reduced state [@B54]. To further clarify the mechanism for the apoptosis induced by downregulation of *HJURP*, we found a strongly increased ROS-positive cells and proteins involved in ROS metabolism (Figure [4](#F4){ref-type="fig"}), which could be regulated by the PPARγ-SIRT1 feedback loop and could link oxidative stress and apoptosis together [@B22],[@B31],[@B36]. These results suggested that the homeostasis of ROS metabolism was disrupted by downregulation of *HJURP* in the BCa cells, and therefore could lead to irreversible oxidative modifications of lipid, protein, or DNA, resulting in oxidative stress-induced apoptosis [@B55]. Taken together, our results suggested that the increased apoptosis rate of BCa cells triggered by *HJURP* reduction might be via ROS-related pathway and oxidative stress.

Another interesting phenomenon we observed was that in the *HJURP*-*siRNA*-treated BCa cells, protein level of PPARγ was strongly upregulated, whereas the ratio of p-SIRT1/t-SIRT1 were considerably downregulated, as well as its substrate acetylated p53 was increased (Figure [4](#F4){ref-type="fig"}). Since PPARγ-SIRT1 feedback loop could play a key role in the regulation of antioxidant response, apoptosis and cell cycle [@B26],[@B28],[@B31],[@B33], thus we treated the BCa cells with PPARγ-antagonist GW9662 to deactivate PPARγ protein [@B25] and RSV to activate SIRT1 [@B56]. With the treatment of GW9662 and RSV, we noticed a significantly recovery of proliferation inhibition as well as scavenge of ROS status in *HJURP*-*siRNA*-treated BCa cells and a recovery of induced Catalase (Figure [4](#F4){ref-type="fig"}), one of the most important antioxidant enzymes for degradation of hydrogen peroxide [@B34].

Moreover, overrepresentation analysis based on microarray raw data and DAVID suggested that the genes involved in p53 signaling pathway were affected in bladder cancer, linked with cell cycle arrest at G1 and G2 phase ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S2). Consistently, we also observed a significantly induced cell cycle arrest at G0/G1 phase, followed by downregulation of protein involved in G0/G1 to S phase progression (CCNA1/2, CCND1 and CDK2/4), and upregulation of their upstream proteins p-GSK-3β/t-GSK3β (Figure [5](#F5){ref-type="fig"}). Western blot analysis also exhibited a strongly downregulation of p-ERK1/2 and CCND1 after depleting *HJURP* (Figure [5](#F5){ref-type="fig"}), as reported by Meloche *et al* that activation of ERK1/2 is necessary for G1 to S phase progression by targeting CCND1 [@B57]. In contrast, no significant alterations of ROS status ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S9A-B), cell cycle ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S9C-D) and apoptosis ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S10) in the *HJURP*-overexpressed BCa cells were observed. However, a similar cell cycle arrest was noticed in the *CENP-A-siRNA*-treated BCa cells (Figure [7](#F7){ref-type="fig"}D-E), suggesting that the effect of HJURP on cell cycle regulation could be through CENP-A. Moreover, our results revealed no significant alterations of ROS production ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S11) and apoptotic rate ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S12), indicating a major effect of CENP-A on cell cycle regulation of BCa cells.

Since our transcriptome analysis suggested a link between cell cycle and PPAR signaling pathway in bladder cancer, we therefore pretreated *HJURP*-*siRNA*-treated BCa cells with GW9662 as well, noticing that the PPARγ was not affected at protein level, but a rescued effect on p-SIRT1/t-SIRT1 protein abundance (Figure [6](#F6){ref-type="fig"}), suggesting the PPARγ-SIRT1 feedback loop was interfered. Importantly, deactivation of PPARγ by GW9662 displayed a recovery of cell cycle arrest and upregulation of protein involved in the G0/G1 phase (CCNA1/2, CCND1 and CDK2/4) in the *HJURP*-*siRNA*-treated BCa cells (Figure [6](#F6){ref-type="fig"}). These results showed that *HJURP* deficiency might trigger cell cycle arrest at G0/G1 phase via PPARγ-SIRT1 feedback loop in BCa cells. However, further studies are needed to clarify the direct regulatory link between *HJURP* and PPARγ-SIRT1 feedback loop in tumorigenesis of bladder cancer.

In conclusion, our study suggests that *HJURP* could regulate ROS metabolism and cell cycle via PPARγ-SIRT1 feedback loop and thus contribute to the progression of bladder cancer ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S13).
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![***HJURP* is strongly upregulated in BCa tissues compared with paracancerous tissues and normal bladder tissues. (A)**Gene ontology (GO) and Pathway-Relation-Network (Path-net) analysis based on the GCBI analysis tool suggested that PPAR signaling pathway was correlated with bladder cancer and cell cycle, as well as p53 signaling pathway could be a possible link between bladder cancer and apoptosis. **(B)** qRT-PCR analysis evaluated the gene expression of *HJURP* in bladder cancer tissues was significantly higher than the matched paracancerous tissues. The *GAPDH* value was used as an internal control. \*\*\* p\<0.001. **(C)** Representative double immunofluorescence staining of HJURP (green) in bladder cancer tissues (a-b), paracancerous tissues (c-d) and normal bladder tissues (e-f). The staining of OCT4 (red) was used as a marker of BCa cells. Nuclei were stained by DAPI (blue). The scale bar for C is 100 μm.](jcav08p2282g001){#F1}

![**Downregulation of *HJURP* repressed BCa cell proliferation. (A-C)** qRT-PCR validated the efficiency by using distinct *siRNA* to knockdown *HJURP* at transcriptional level in three BCa cells (T24, EJ and UM-UC-3). All values shown were mean ± SD of triplicate measurements and repeated three times with similar results, \*\* p\<0.01.**(D)** Representative immunofluorescence staining of HJURP (red) in the BCa cells after *HJURP-target-specific-siRNA* treatment (KD) (b, d, f), compared with *control-siRNA* treatment (NC) (a, c, e). Nuclei were stained by DAPI (blue). **(E)** CCK-8 assay was used to detect the viability of distinct BCa cells treated by *control-siRNA* (NC, black line) and *HJURP-target-specific-siRNA* (*HJURP* KD, red line). All values shown were mean ± SD of triplicate measurements and repeated three times with similar results, \* p\<0.05.**(F)** Cell survival of BCa cells UM-UC-3 (a-b), T24 (c-d), EJ (e-f) were revealed by clonogenic survival assay after treatment of *control-siRNA* (NC) and *HJURP-target-specific-siRNA*(*HJURP* KD), cultured in 6-well plates for approximately 14 days. **(G)** Clone number in each well was counted and statistically analyzed in the clonogenic survival assay. \*\* p\<0.01.**(H)** Cell proliferation of BCa cells treated by *control-siRNA* (a, c, e) and *HJURP-target-specific-siRNA* (b, d, f) was detected by Ki-67 staining (green). Nuclei were stained by DAPI (blue). The scale bars for D is 20 μm, for F is 1 cm and for G is 40 µm.](jcav08p2282g002){#F2}

![**Decreased *HJURP*induced BCa cell apoptosis. (A)** Distinct BCa cells (UM-UC-3, T24, EJ) were transfected with *control-siRNA* (a, c, e) and *HJURP-target-specific-siRNA* (b, d, f) for 72h. Detection of cell apoptosis was stained with Annexin V/PI and measured by flow cytometry. (**B**) Statistical analysis of apoptotic rate (%) in the BCa cell lines after transfection treatment. All values shown were mean ± SD of triplicate measurements and repeated three times with similar results, \*\* p\<0.01.**(C)** Western blot analysis for pro-Caspase 3/7/9 and cleaved-Caspase 3/7/9 (c-Caspase 3/7/9), suggesting no strong changes of cleaved Caspases in the *HJURP-target-specific-siRNA-*treated BCa cells compared with the control cells. GAPDH abundance was used as a loading control. Cell types, treatment of *siRNA* and protein masses were indicated. **(D)**TUNEL-test to detect apoptosis (green) in *control-siRNA*-treated BCa cells (a-c) and *HJURP-target-specific-siRNA-*treated BCa cells (d-f). Nuclei were stained by DAPI (blue). The scale bar for D is 40 µm.**(E)** Statistical analysis of TUNEL-test revealed a significant increase of apoptotic cell rate in the EJ, T24 and UM-UC-3 cells after *HJURP-target-specific-siRNA*(*HJURP* KD) treatment. \* p\<0.05.](jcav08p2282g003){#F3}

![***HJURP*deficiency induced ROS status in BCa cells accompanied by alterations of PPARγ, phosphorylated/total SIRT1 and acetylated-p53. (A)**After transfection by *control-siRNA* (NC) or *HJURP-target-specific-siRNA*(*HJURP* KD), distinct BCa cells were stained with DCFH-DA to detection ROS, measured by flow cytometry. **(B)** Statistical analysis of relative fluorescence of ROS in the *siRNA*-transfected BCa cell lines. All values shown were mean ± SD of triplicate measurements and repeated three times with similar results. \*\* p\<0.01. **(C)** Western blot analysis for proteins involved in ROS and apoptosis: Catalase, Heme oxygenase 1 (Hmox-1), Superoxide dismutase 2 (SOD2), Bax, Bcl-xl, acetylated-p53 (acetyl-p53), PPARγ and phosphorylated/total SIRT1 (p-SIRT1/t-SIRT1). GAPDH abundance was used as a control. Cell types, treatment of *siRNA* and protein masses were indicated. **(D)** Respectively immunofluorescence staining of PPARγ (a-b), SIRT1 (c-d), Catalase (e-f) and acetyl-p53 (g-h) in the T24 cells after *control-siRNA* and *HJURP-target-specific-siRNA*treatment. Nuclei were stained by DAPI (blue). The scale bar for D is 20 μm. **(E)** UM-UC-3 and EJ cells were pretreated with GW9662 at 0 μM, 20 μM and 40 μM for 12 h, and continually transfected with *control-siRNA*and *HJURP-target-specific-siRNA*for another 72 h. Flow cytometry was used to detect ROS status in distinct BCa cells stained with DCFH-DA. **(F)** Relative fluorescence of ROS in the GW9662-pretreated UM-UC-3 (a) and EJ (b) cells after *siRNA* transfection. \* p\<0.05, \*\* p\<0.01. **(G)** Western blot analysis for Catalase in the GW9662-pretreated UM-UC-3 and EJ cells after *control-siRNA*or*HJURP-target-specific-siRNA* treatment. GAPDH abundance was used as a control. Cell types, treatment of *siRNA*/GW9662 and protein masses were indicated.](jcav08p2282g004){#F4}

![**Knockdown of *HJURP*induced cell cycle arrest at G0/G1 phase in BCa cells. (A)**Flow cytometry analysis for UM-UC-3 (a-b), T24 (c-d) and EJ cells (e-f) treated with *control-siRNA*(a, c, e) and *HJURP-target-specific-siRNA*(b, d, f) for 72 h. **(B)** Alteration of percentages (%) of cell populations at different stages of cell cycles in UM-UC-3 (a), T24 (b) and EJ cells (c) was statistically analyzed. All values shown were mean ± SD of triplicate measurements and repeated three times with similar results. \* p\<0.05, \*\* p\<0.01, \*\*\* p\<0.001. **(C)** Western blot analysis of proteins involved in the G0/G1 cell cycle regulation (CCNA1/2, CCND1, CDK2/4) as well as phosphorylated/total ERK1/2 and phosphorylated/total GSK-3β in the BCa cells. GAPDH abundance was used as a control. Cell types, treatment of *siRNA* and protein masses were indicated.](jcav08p2282g005){#F5}

![**Recovery of *HJURP* deficiency-induced cell cycle arrest at G0/G1 phase by PPARγ-antagonist GW9662 in BCa cells. (A)** UM-UC-3 (a-d) and EJ (e-h) cells were pretreated with GW9662 at 0 μM (a-b, e-f), 20 μM (c, g), 40 μM (d, h) for 12 h, and continually transfected by *control-siRNA*(a, e) and *HJURP-target-specific-siRNA*(b-d, f-h) for another 72 h. The alteration of percentages (%) of cell populations at different stages of cell cycles were measured by flow cytometry. **(B)** Statistically analysis of recovered cell cycle arrest at G0/G1 phase by GW9662. All values shown were mean ± SD of triplicate measurements and repeated three times with similar results, \* p\<0.05, \*\* p\<0.01. **(C)**Western blot analysis of protein abundance of CDK2/4, CCNA1/2, CCND1, PPARγ and phosphorylated/total SIRT1 using total protein isolated from cell lysates. GAPDH was used as a loading control. Cell types, treatment of *siRNA*/GW9662 and protein masses were indicated.](jcav08p2282g006){#F6}

![**CENP-A may be involved in the HJURP-reduction induced cell cycle arrest. (A)** Western blot analysis of CENP-A protein in the *HJURP-control-siRNA*(NC) and *HJURP-target-specific-siRNA*(*HJURP* KD) treated BCa cells (UM-UC-3, T24 and EJ). **(B)** Western blot analysis of CENP-A protein in the *control*(Vector) and *pWSLV-11-HJURP* plasmid (*HJURP*-HA) transfected BCa cells (UM-UC-3, T24 and EJ). **(C)** Western blot analysis for the proteins involved in cell cycle regulation (CCNA 1/2, CCND1, CDK2, CDK4) in the *CENP-A-control-siRNA*(NC) and*CENP-A-target-specific-siRNA*(*CENP-A* KD) treated BCa cells (UM-UC-3, T24 and EJ). GAPDH was used as a loading control. Cell types and protein masses were indicated. **(D)** Flow cytometry analysis of alteration of percentages (%) of cell populations at different stages of cell cycles in the *CENP-A-control-siRNA*(NC) and*CENP-A-target-specific-siRNA*(*CENP-A* KD) treated BCa cells (UM-UC-3, T24 and EJ). **(E)** Changes of percentages (%) of cell populations at different stages of cell cycles in UM-UC-3 (a), T24 (b) and EJ cells (c) was statistically analyzed. All values shown were mean ± SD of triplicate measurements and repeated three times with similar results. \* p\<0.05, \*\* p\<0.01.](jcav08p2282g007){#F7}
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